You are here

Article Text

Article menu
Download PDFPDF
Short report
Kinase expression in angiomatoid fibrous histiocytoma: panTRK is commonly expressed in the absence of NTRK rearrangement
  1. Ana Cristina Vargas1,2,
  2. Christopher Joy3,
  3. Fiona M Maclean2,
  4. Fiona Bonar2,
  5. Daniel D Wong4,
  6. Anthony J Gill1,5,
  7. Alison L Cheah2
  1. 1 The University of Sydney, Sydney, New South Wales, Australia
  2. 2 Douglass Hanly Moir Pathology, North Ryde, New South Wales, Australia
  3. 3 Sullivan Nicolaides Pathology Central Laboratory Bowen Hills, Fortitude Valley, Queensland, Australia
  4. 4 PathWest Laboratory Medical WA, Nedlands, Western Australia, Australia
  5. 5 Royal North Shore Hospital, St Leonards, New South Wales, Australia
  1. Correspondence to Dr Ana Cristina Vargas, Douglass Hanly Moir Pathology, Macquarie Park, NSW 2113, Australia; cvargas{at}dhm.com.au

Abstract

Angiomatoid fibrous histiocytoma (AFH) is a soft tissue tumour of intermediate (rarely metastasising) malignant potential, which harbours EWSR1/FUS gene fusions. These tumours can express anaplastic lymphoma kinase (ALK) in the absence of gene rearrangement or copy number alteration and can also coexpresses Pan-TRK immunohistochemistry (IHC). All EWSR1/FUS-rearranged AFH were retrieved from the files of three institutions and Pan-TRK (EPR17341), ALK and BRAF V600E IHC were performed. Fourteen AFH cases were identified, which included three cases of intracranial mesenchymal tumours with FET-CREB fusions. PanTRK and ALK positive immunostaining was identified in 9 (64.2%) and 12 (85.7%) cases, respectively. No NTRK or ALK translocations or increased copy number/amplification were identified in all eight cases which had fluorescence in situ hybridisation and/or next generation sequencing for NTRK1-3 and ALK available for assessment. None of the cases expressed BRAF-V600E.

Although our study is limited, our report is the first to document PanTRK expression in AFH in the absence of identifiable NTRK1-3 gene alterations.

  • Soft Tissue Neoplasms
  • IMMUNOHISTOCHEMISTRY
  • Biomarkers, Tumor

https://doi.org/10.1136/jcp-2023-209225

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Handling editor David Creytens.

    • Collaborators N/A.

    • Contributors ALC conceived the study, reviewed samples, edited the draft and scored IHC. ACV wrote the manuscript, reviewed samples and scored IHC. DDW, FMM, FB and AJG contributed and reviewed cases and edited the final draft.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.